Premium
Haemostatic changes during continuous oestradiolprogestogen treatment of postmenopausal women
Author(s) -
SPORRONG TOMMY,
MATTSSON LARSÅKE,
SAMSIOE GÖRAN,
STIGENDAL LENNART,
HELLGREN MARGARETA
Publication year - 1990
Publication title -
bjog: an international journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.157
H-Index - 164
eISSN - 1471-0528
pISSN - 1470-0328
DOI - 10.1111/j.1471-0528.1990.tb02451.x
Subject(s) - megestrol acetate , medicine , norethisterone , partial thromboplastin time , norethisterone acetate , climacteric , fibrinogen , factor vii , hormone replacement therapy (female to male) , platelet , progestogen , endocrinology , hormone , menopause , coagulation , population , testosterone (patch) , research methodology , environmental health , cancer
Summary. To identify changes in haemostatic balance during continuous oestradiol‐progestogen treatment, 60 postmenopausal women with climacteric complaints, mean age 55.4 years (range 44–68) were randomly allocated to receive one of four hormone replacement regimens for one year. All four formulations were administered daily and continuously, each contained 2 mg of 17 β‐oestradiol in combination with either norethisterone acetate, 1 mg (group A) or 0.5 mg (group B) or megestrol acetate, 5 mg (group C) or 2.5 mg (group D). No significant changes occurred during treatment within or between the groups in platelet count, fibrinogen and 2‐antiplasmin. Activated partial thromboplastin time was shortened (P<0.05) in group D and a decline in factor VII activity and antigen (P<0.001) and in AT1II activity (P<0.05) was noted in group A. Protein C tended to decline in all treatment groups but statistically significant changes were noted only in groups A and C. Two women developed crural thrombosis during the observation period.